Efficacy News and Research

RSS

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.

18 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

Teva Pharmaceutical Industries Ltd. today presented data from a sub-analysis of a Phase III clinical trial of Milprosa (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization.

18 Apr 2013

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

18 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

UI Health to launch EPIC program to cut frequent ER visits, readmissions to hospital

The University of Illinois Hospital & Health Sciences System is taking steps to reduce frequent emergency room visits and readmissions to the hospital.

17 Apr 2013

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.

17 Apr 2013

New research shows that use of social media can offer additional support to older people

The use of social media by older people can offer valuable additional support in cases of sickness and diseases, new research from the University of Luxembourg has shown.

17 Apr 2013

Researchers report progress on non-invasive method to assess kidney function

Researchers may have found a way to block kidney-destroying inflammation and help damaged kidney cells recover.

17 Apr 2013

Study finds no evidence that digoxin increases mortality in patients with atrial fibrillation

A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation, the opposite of results just published by another group in the same journal analyzing the same data.

17 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

Efficacy News and Research

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

UI Health to launch EPIC program to cut frequent ER visits, readmissions to hospital

Flunisyn Phase 2a trial data shows positive results in elderly population

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

New research shows that use of social media can offer additional support to older people

Researchers report progress on non-invasive method to assess kidney function

Study finds no evidence that digoxin increases mortality in patients with atrial fibrillation

COPD phase III study by Almirall and Forest Laboratories announces positive results

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Mental exercise may help prevent cognitive decline in healthy older adults

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News